Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: DREAM is reduced in synovial fibroblasts of patients with chronic arthritic pain: is it a suitable target for peripheral pain management?

Figure 1

Qualitative results of reverse transcription-polymerase chain reactions (PCRs) using DREAM primer and DREAM nested primer. (a) DREAM amplicons of 409 base pairs (bp) in size in total RNA derived from cerebellum and spinal cord, which served as positive controls. (b) Amplicons of the expected size after reamplification from total RNA isolated from normal synovial fibroblast-like cells (NSFLCs) and osteoarthritis synovial fibroblast-like cells (OA-SFLCSs). (c) DREAM amplicon of 409 bp and the amplicon resulting from nested PCR, starting from the PCR mix, which did not show any product on the agarose gel. The size of the smaller amplicon corresponds to the expected size of 276 bp. (d) Sequence of the amplicon. Positions of primers are highlighted in bold (DREAM forward and reverse) and bold italics (nested DREAM forward and reverse). DREAM, downstream regulatory element antagonist modulator.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us